Incidence and survival of childhood central nervous system tumors in Denmark, 1997–2019

Anne Sophie Lind Helligsoe1,2 | Line Kenborg3 | Louise Tram Henriksen1,2 | Aparna Udupi4 | Henrik Hasle1 | Jeanette Falck Winther2,3

1Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
2Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark
3Childhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark
4Biostatistical Advisory Service (BIAS), Faculty of Health, Aarhus University, Denmark

Correspondence
Anne Sophie Lind Helligsoe, Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, & Department of Clinical Medicine, Faculty of Health, Aarhus University, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark.
Email: aslf@dadlnet.dk

Funding information
This work was supported by the Danish Childhood Cancer Foundation, Lizzy and Mogens Staal Foundation, Dagmar Marshall Foundation, Temrermerster Jørgen Holm & Hustru Elisa F. Hansen Foundation, Health Research Foundation of Central Denmark Region, and Aarhus University. The funders had no role in designing or conducting the study.

Abstract
Background:Incidence rates in Denmark of central nervous system (CNS) tumors remain among the highest in the world. Survival rates, however, have improved in the past decades in high-income countries.

Methods:We analyzed incidence and survival of childhood CNS tumors in Denmark diagnosed from 1997 to 2019 based on data from the Danish Childhood Cancer Registry and information on histological types, tumor localization, and treatment from medical records.

Results:From 1997 to 2019, 949 children<15 years were diagnosed with a CNS tumor. Age-standardized incidence was 42.1 (95% CI, 39.4–44.6) per million person-years and stable during this period. Age-specific incidence for children aged 0–4 years was 47.7 per million. More than one-third (n = 374, 39.4%) were treated with surgery alone. Overall survival rates 5 and 10 years after diagnosis were 77.6% (95% CI, 74.7–80.2) and 74.7% (95% CI, 71.7–77.5). Five-year overall survival improved from 73.0% (95% CI, 68.9–76.7) in 1997–2008 to 83.2% (95% CI, 79.2–86.4) in 2009–2019 (p-value < 0.0001) in children aged 0–4 years (p = 0.0006).

Conclusion:Incidence rates are stable but remain among the highest in the world. Despite improved survival rates in recent years in younger children, some subtypes still have a poor prognosis.

KEYWORDS
central nervous system tumor, childhood cancer, childhood cancer survivors, incidence, survival
1 | INTRODUCTION

Although cancer in children is rare, it is the second leading cause of death among children in high-income countries. Central nervous system (CNS) tumors are the most common solid malignancy in childhood, representing 20% of all cancers observed in children. Furthermore, the mortality rate is high. Thus, CNS tumors contribute considerably to the overall childhood cancer incidence and mortality of childhood cancer. A study of the international incidence of childhood cancer between 2001 and 2010 reported an increase in the global incidence of childhood cancer, including CNS tumors. However, the incidence of CNS tumors varied across populations and appeared to be highest (>20 per million person-years) in high-income countries including the United States and the Nordic countries, and lowest in low- and middle-income countries. Whether the high incidence can be explained by biological factors, the availability of better diagnostic facilities, and/or more complete registration of cancer diagnoses in national registries remains uncertain. Since 1943, data on the incidence of cancer in the Danish population have been registered in the Danish Cancer Registry. Using these complete and comprehensive Danish data, a recently published study reported an increase in childhood CNS tumors, with an age-standardized rate reaching 43.8 per million person-years in 1977–2014, but the study lacked detailed information on histological types and treatment. In Europe, annual incidence rates range from 22 to 44 per million person-years and increased from the 1980s to the 1990s, with a decline or stabilization in the years after 2000.

Historically, survival of pediatric CNS tumors has improved in Denmark, from a 5-year survival rate of 66% in the 1980s to stable rates of 70%–80% from 2000 to 2020 according to WHO databases. Changes in incidence and survival are caused by numerous factors such as access to health care and improved diagnostic and treatment facilities, and studies reporting the development over time can form the basis for etiological research and monitor the progress in treatment of childhood cancer. As CNS tumors are a heterogeneous group of malignancies with varied incidences and survivals, detailed tumor information is crucial in these types of studies. Thus, in the present study, we analyzed incidence and survival in children with CNS tumors in Denmark diagnosed, 1997–2019, according to histological type and tumor localization. We also reported the treatment modalities of distinct CNS tumors that have not previously been reported in Danish children in incidence and survival studies.

2 | MATERIALS AND METHODS

2.1 | Patient cohort

Since 1985, all children diagnosed with cancer in Denmark have been registered by clinicians in the nationwide clinical database, the Danish Childhood Cancer Registry (DCCR), with the overall aim of monitoring the quality of childhood cancer care in Denmark. The DCCR is linked to the Danish National Patient Registry, the National Pathology Registry, and the Danish Cancer Registry using the unique national identification number assigned to all permanent residents in Denmark at birth or immigration. We obtained information on all children below 15 years of age, living in Denmark who had a primary CNS tumor diagnosed from 1 January 1997 to 31 December 2019 (n = 1093), including information on known syndromes predisposing to CNS tumors (neurofibromatosis type 1 or 2, tuberous sclerosis, Gorlin–Goltz, or multiple endocrine neoplasia type 1), histological type, treatment for first primary tumor, and survival. All patients with neurofibromatosis type 1 or 2 and low-grade glioma as well as patients with tuberous sclerosis and subependymal giant cell astrocytoma were registered. Children with other tumors in the CNS such as Langerhans cell histiocytosis, lipoma, lymphoma, hemangioma, hamartoma, sarcoma, and bone sarcoma were excluded (n = 144), as they are not classified as classical CNS tumors. Information on children aged 15–18 years was not complete for the entire study period and was therefore not included. The final patient cohort consisted of 949 children.

To describe overall and specific treatment modalities, we validated all information on tumor localization and treatment characteristics obtained from the DCCR. Missing information was obtained by systematically reviewing and abstracting relevant information from all medical reports except 62 (6.5%), which were not available.

2.2 | Tumor classification

Tumors were classified according to localization: cerebellum, cerebrum, supratentorial central area, brain stem, hypothalamic and pituitary area, optic nerve or chiasma, pineal gland, or intraspinal. Both benign and malignant tumors were classified histologically on the basis of the International Classification of Diseases for Oncology (ICD-O) according to main diagnostic group III CNS and miscellaneous intracranial and intraspinal neoplasms and the subgroup Xa Intracranial and intraspinal germ cell tumors in the International Classification of Childhood Cancer, third edition.
(ICCC-3) (Table S1). According to 2016 CNS WHO, we adopted the terminology “embryonal CNS Tumor NOS” to replace primitive neuroectodermal tumor (CNS-PNET). Atypical teratoid/rhabdoid tumor (ATRT) was incorporated in the ICD-O as a new entity in 2000. Optic nerve glioma and brain stem glioma were accepted without biopsy due to characteristic presentation.

2.3 | Statistical methods

2.3.1 | Incidence

The overall age-specific incidence rates (ASI) per million person-years were calculated for all types of CNS tumors in the three age groups 0–4 years, 5–9 years, and 10–14 years according to date of birth and calendar year, with the annual Danish population at midyear from Statistics Denmark as the denominator. ASI was calculated for specific histological types and localization in children aged 0–4 years, 5–9 years, and 10–14 years and separately for boys and girls.

Age-standardized incidence rates (ASRs) expressed per million person-years were derived by direct standardization, using the weight of the world standard population as proposed by Segi in order to compare with other countries and to eliminate changes in the age distribution during the study period. ASRs were calculated overall and for each year.

Finally, we evaluated changes in incidence rate over time by analyzing the age-standardized incidence rates using restricted cubic spline smoother for the year of diagnosis with four knots, in a Poisson regression model. A joint post hoc test of the coefficients of the higher order spline variables gave a formal test for nonlinear trend.

2.3.2 | Survival

Survival was defined as time from diagnosis to death from any cause and presented with median with lower and upper quartiles. Patients were censored at date of emigration or 31 December 2019, whatever occurred first. We calculated both 5- and 10-year overall survival (OS) for all histological types combined and for specific subgroups for the entire study period and for the two time periods (1997–2008 and 2009–2019) separately. All survival rates were reported with 95% confidence intervals (95% CIs). Survival function was estimated by the Kaplan–Meier method and presented in plots in children aged 0–4 years and 5–14 years to facilitate comparison with previous studies. The difference in survival functions was estimated with the log-rank test. Two children died at birth. To include these two cases in the survival analyses, 1 day was added to all cases.

Survival function and 95% CIs for each gender, age group, time period, and localization were calculated for individual tumor types. To identify possible factors influencing survival, the risk of death according to gender, age group, time period, and localization was estimated by hazard ratios (HRs) and their 95% CIs using univariate and multivariate Cox proportional hazards regression models. Reference categories were selected logically as the first category (boys, children aged 0–4 years, supratentorial location, 1998–2008).

3 | RESULTS

3.1 | Patient cohort

After exclusion of the 144 non-CNS tumors, we identified 949 children (468 girls, 49.3%) diagnosed with a CNS tumor in Denmark who were younger than 15 years of age at diagnosis. On average, 41.3 new cases were diagnosed annually (Table 1). Children aged 0–4 years accounted for 38.2% of all the cases, followed by children aged 5–9 years (33.7%) and children aged 10–14 years (28%). The median follow-up time was 7.5 years (quartiles 1.8–14.9). Around 7% (n = 69) had a predisposing condition: 55 children (5.8%) were diagnosed with neurofibromatosis 1 or 2, 10 (1.1%) with tuberous sclerosis, and 4 (0.4%) with either Gorlin–Goltz syndrome or multiple endocrine neoplasia type 1.

3.2 | Treatment characteristics

In total, 374 (39%) children were treated only surgically and 93 patients were observed without therapy (Table 1). Surgery, either alone or combined with radiation or chemotherapy, was performed in 748 children (79%) ranging from macroscopically complete resection (n = 418) to partial resection (n = 211) and biopsy (n = 86). In 33 (4.4%) children undergoing surgery, the extent of surgery was unknown. Chemotherapy was administered in 328 (35%) children and radiotherapy in 293 (31%) children. Treatment with radiotherapy was equally distributed in the two time periods: 12.6 children per year received radiotherapy in 1997–2008 (30.5% of children diagnosed) compared to 12.9 children per year from 2009 to 2019 (31.2% of children diagnosed). More children were treated with chemotherapy in 2009–2019 (183/494, 37.0% of children diagnosed) compared to 1997–2008 (145/455, 31.9%). Information about radiation fields was not available.
3.3 | Tumor localization and subgroups according to ICCC-3

The most predominant tumor location was the cerebellum (n = 342, 36%) followed by the cerebrum (n = 179, 19%), supratentorial central area (n = 89, 9.4%), hypothalamus or pituitary region (n = 84, 8.9%), brain stem (n = 73, 7.7%), optic nerve or chiasma (n = 65, 6.8%), intraspinal (n = 45, 4.7%), and pineal gland (n = 22, 2.3%) (Table 1). The most common histological types were astrocytoma (n = 385, 40.6%) followed by embryonal tumors (n = 160, 16.9%) (Table 2). In 171 cases (18%), the diagnoses were not verified histologically, because it was not necessary to establish the diagnosis or the tumor was surgically inaccessible (data not shown).

Medulloblastoma (n = 124, 50 girls) was diagnosed predominantly in children aged 5–9 years (n = 54), followed by children aged 0–4 years (n = 46) and less frequently at 10–14 years (n = 24) (Table S2). ATRT (n = 19, 14 girls) was diagnosed primarily in the very young children. The majority of these children received both chemotherapy (n = 16) and radiation (n = 13), two received only radiation, and treatment information was unavailable in two children.

Looking further into tumors in children <24 months at diagnosis (n = 147, 76 girls), the three most dominant histological types were astrocytoma (n = 48), including 21 with pilocytic astrocytoma, medulloblastoma (n = 16), and ATRT (n = 16) (Table S2).

The three most dominant histological types among children with tumors with an intraspinal location (n = 45, 22 girls) were astrocytoma (n = 15), other specified intraspinal neoplasm (n = 15), and ependymoma (n = 9) (Table S4).

### Table 1: Characteristics of children <15 years diagnosed with a CNS tumor in Denmark, 1997–2019

|                        | n  | %  |
|------------------------|----|----|
| Patients               | 949| 100|
| Gender                 |    |    |
| Girls                  | 468| 49.3|
| Boys                   | 481| 50.7|
| Median follow-up (interquartile range) | 7.5 (1.8–14.9) |
| Year of diagnosis      |    |    |
| 1997–2005              | 377| 39.7|
| 2006–2013              | 319| 33.6|
| 2014–2019              | 263| 27.7|
| Age at cancer diagnosis|    |    |
| 0–4                    | 363| 38.2|
| 5–9                    | 320| 33.7|
| 10–14                  | 266| 28.0|
| Location of tumor      |    |    |
| Cerebellum             | 342| 36.0|
| Cerebrum               | 179| 18.9|
| Supratentorial central area | 89 | 9.4 |
| Hypothalamus or pituitary region | 84 | 8.9 |
| Brain stem             | 73  | 7.7 |
| Optic nerve or chiasma | 65  | 6.8 |
| Intraspinal            | 45  | 4.7 |
| Pineal gland           | 22  | 2.3 |
| Unknown                | 50  | 5.3 |
| Predisposing syndrome  |    |    |
| Neurofibromatosis type 1 or 2 | 55 | 5.8 |
| Tuberous sclerosis     | 10  | 1.1 |
| Gorlin–Goltz or multiple endocrine neoplasia type 1 | 4 | 0.4 |
| Cancer treatment       |    |    |
| Surgery (only)         | 374| 39.4|
| Chemotherapy           | 328| 34.6|
| Radiation              | 293| 30.9|
| No treatment           | 93  | 9.7 |
| No treatment information | 41  | 4.3 |
| Surgery                | 748 |    |
| Macroscopically complete | 418 | 55.9 |
| Partial resection      | 211 | 28.2 |
| Biopsy only            | 86  | 11.5|
| Extent unknown         | 33  | 4.4 |

3.4 | Age-standardized and age-specific incidences

The overall ASR for the entire study period was 42.1 (95% CI 39.6–44.9, Figure 1). The overall ASR for brain tumors only was 40.1 (95% CI 37.6–42.8) per million person-years.

ASR was clinically stable from 1997 to 2019 within the range of 31.0–61.7 although the statistical test indicated evidence for nonlinear relation between log of the incidence and calendar year (p = 0.0071).

ASIs of all CNS tumors in the three age groups are shown in Table S3. The highest ASI was observed in children aged 0–4 years, with 47.7 per million person-years, followed by 40.7 in children aged 5–9 years and 34.7 in children aged 10–14 years (Figure S1).

3.5 | Incidence according to ICCC-3 subgroups

Astrocytomas (n = 385, 214 girls) were the most predominant histological type in children aged 0–4 years, with an ASI of 20.7 per million person-years (Table S3) followed by 16.8 in children aged 5–9 years and 13.4 in
**TABLE 2** Subgroups according to the International Classification of Childhood Cancer, third edition (ICCC-3) of all CNS tumors diagnosed in Denmark in children <15 years from 1997 to 2019 presented with median age, gender distribution, and treatment information

| Subgroup                                      | n   | % of CNS tumors | Age at diagnosis, median (range) | Gender distribution, Girls, n | % | Surgery (n) | Chemotherapy (n) | Radiation (n) |
|-----------------------------------------------|-----|-----------------|----------------------------------|------------------------------|---|-------------|------------------|---------------|
| All CNS tumors                                | 949 | 100             | 7.0 (0–15)                       | 468                          | 49.3 | 748         | 328              | 293           |
| IIIa. Ependymomas and choroid plexus tumor    | 77  | 8.1             | 3.0 (0.1–14.9)                   | 35                           | 45.5 | 73          | 31               | 38            |
| IIIa1. Ependymoma                             | 56  | —               | 5.1 (0.1–14.9)                   | 21                           | 37.5 | 53          | 25               | 35            |
| IIIa2. Choroid plexus tumor                   | 21  | —               | 1.0 (0.2–10.6)                   | 14                           | 66.7 | 20          | 6                | 3             |
| IIIb. Astrocytomas                            | 385 | 40.6            | 6.7 (0–14.9)                     | 21                           | 55.6 | 309         | 96               | 62            |
| IIIb1. Filoctic                               | 200 | —               | 7.1 (0.1–14.7)                   | 111                          | 55.5 | 192         | 31               | 17            |
| IIIb2. Optic gloma                            | 50  | —               | 3.8 (0.4–12.1)                   | 33                           | 66.0 | 11          | 23               | 6             |
| IIIb3. Glioblastoma                           | 23  | —               | 8.0 (0.9–14.5)                   | 12                           | 52.2 | 20          | 16               | 14            |
| IIIb4. Anaplastic                             | 17  | —               | 8.0 (3.0–14.7)                   | 10                           | 58.9 | 16          | 9                | 12            |
| IIIb5. Diffuse                                | 15  | —               | 9.2 (1.0–13.8)                   | 8                            | 53.3 | 14          | 5                | 4             |
| IIIb6. Subependymal giant cell                | 12  | —               | 9.9 (0.4–14.9)                   | 5                            | 41.7 | 11          | <3               | 0             |
| IIIb7. Pleomorphic xanthoastrocytoma           | 9   | —               | 10.3 (3.7–13.5)                  | 7                            | 77.8 | 8           | <3               | <3            |
| IIIb8. Pilocytic                              | 4   | —               | 9.8 (2.9–14.1)                   | 2                            | 50.0 | 4           | <3               | 0             |
| IIIb9. Fibrillary                             | 4   | —               | 2.7 (0.74–13.3)                  | 3                            | 75.0 | 4           | <3               | 0             |
| Other                                         | 51  | —               | —                                | —                            | —    | —           | —                | —             |
| IIIc. Intracranial and intraspinal embryonal tumors | 160 | 16.9           | 5.7 (0–14.3)                     | 72                           | 45.0 | 150         | 130              | 113           |
| IIIc1. Medulloblastoma                        | 124 | —               | 5.9 (0.1–14.3)                   | 50                           | 40.3 | 118         | 105              | 91            |
| IIIc2. Embryonal CNS tumor NOS                | 16  | —               | 7.1 (0.6–12.3)                   | 8                            | 50.0 | 15          | 10               | 9             |
| IIIc3. Medullopethelioma                      | <6  | —               | —                                | —                            | —    | —           | —                | —             |
| IIIc4. Atypical teratoid/rhabdoid tumor       | 19  | —               | 1.3 (0–11.5)                     | 14                           | 73.7 | 16          | 15               | 13            |
| IIId. Other gliomas                           | 66  | 7.0             | 6.9 (0.6–15.0)                   | 31                           | 47.0 | 33          | 24               | 26            |
| IIId1. Oligodendrogloma                       | 13  | —               | 9.4 (0.6–15.0)                   | 7                            | 53.9 | 12          | 3                | 3             |
| IIId2. Mixed and unspecified glioma           | 53  | —               | 6.2 (1.1–14.8)                   | 24                           | 45.3 | 21          | 23               | 23            |
| IIIe. Other specified intracranial and intraspinal neoplasms | 152 | 16.0           | 8.8 (0–15)                       | 67                           | 44.1 | 129         | 15               | 24            |
| IIIe1. Pituitary adenoma and carcinoma        | 25  | —               | 10.2 (0.9–14.8)                  | 9                            | 36.0 | 15          | <3               | 2             |
| IIIe2. Cranioopharyngioma                     | 35  | —               | 7.4 (0–14.5)                     | 16                           | 45.7 | 34          | 0                | 6             |
| IIIe3. Pineal parenchymal tumor               | 11  | —               | 11.1 (0.9–15.0)                  | 7                            | 63.6 | 4           | 3                | 5             |

(Continues)
TABLE 2 (Continued)

| IIle4. Mixed glial-neuronal tumor | 40 | — | 9.6 (0–14.4) | 20 | 50.0 | 38 | 9 | 8 |
| IIle5. Dysembryoblastic neuroepithelial tumor (DNET) | 18 | — | 10.1 (0.4–14.3) | 3 | 16.7 | 17 | <3 | <3 |
| IIle6. Ganglioglioma | 17 | — | 8.8 (0.6–14.7) | 10 | 58.8 | 15 | 0 | <3 |
| IIle7. Schwannoma | <6 | — | 8.1 (1.4–14.9) | 2 | 33.3 | 6 | <3 | 0 |
| III. Unspecified intracranial and intraspinal neoplasms | 15 | 1.6 | 8.7 (0.0–13.5) | 5 | 33.3 | 14 | <3 | <3 |
| IIIl1. Meningioma | 15 | — | 8.7 (0–13.5) | 5 | 33.3 | 14 | <3 | <3 |
| Xa. Intracranial and intraspinal germ cell tumors | 32 | 3.4 | 9.8 (0.0–14.7) | 16 | 50.0 | 28 | 22 | 21 |
| Xa1. Germinoma | 18 | — | 10.4 (13.9–14.7) | 8 | 44.4 | 15 | 17 | 17 |
| Xa2. Non-germinoma germ cell tumors | 14 | — | 3.7 (0–14.7) | 8 | 57.1 | 13 | 4 | 4 |

TABLE 2 (Continued)

| n | % of CNS tumors | Age at diagnosis, median (range) | Gender distribution, Girls, n | % | Surgery (n) | Chemotherapy (n) | Radiation (n) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Unclassified | 62 | 6.5 | 6.5 (0.0–14.1) | 28 | 45.2 | 12 | 8 | 7 |

### 3.6 Survival

At the end of the period, 232 (24.5%) had died, with a median time after diagnosis of 7.0 years (quartiles 5.3–11.1). Five-year OS for all tumors combined was 77.6% (95% CI 74.7–80.2) (Table 3). Five-year OS improved in children aged 0–4 years from 68.5% (95% CI 61.2–74.7) in 1997–2008 to 83.6% (95% CI 76.9–88.6) in 2009–2019 (p = 0.0006). The 5-year OS also increased from 75.7% (95% CI 70.4–81.0) in 1997–2008 to 81.5% (95% CI 76.9–88.6) in 2009–2019 (p = 0.0006). When stratifying the 5-year OS in children aged 0–4 years from 68.5% (95% CI 61.2–74.7) in 1997–2008 to 83.6% (95% CI 76.9–88.6) in 2009–2019 (p = 0.0006), the increase was most significant between 2009 and 2019 (p = 0.0001) (Figure 2).

When stratifying the 5-year OS on age at diagnosis, survival improved from 68.5% (95% CI 61.2–74.7) in 1997–2008 to 83.6% (95% CI 76.9–88.6) in 2009–2019 (p = 0.0006). The 5-year OS also increased from 75.7% (95% CI 70.4–81.0) in 1997–2008 to 81.5% (95% CI 76.9–88.6) in 2009–2019 (p = 0.0006). When stratifying the 5-year OS on age at diagnosis, survival improved from 68.5% (95% CI 61.2–74.7) in 1997–2008 to 83.6% (95% CI 76.9–88.6) in 2009–2019 (p = 0.0006). The 5-year OS also increased from 75.7% (95% CI 70.4–81.0) in 1997–2008 to 81.5% (95% CI 76.9–88.6) in 2009–2019 (p = 0.0006). When stratifying the 5-year OS on age at diagnosis, survival improved from 68.5% (95% CI 61.2–74.7) in 1997–2008 to 83.6% (95% CI 76.9–88.6) in 2009–2019 (p = 0.0006). The 5-year OS also increased from 75.7% (95% CI 70.4–81.0) in 1997–2008 to 81.5% (95% CI 76.9–88.6) in 2009–2019 (p = 0.0006).

When stratifying the 5-year OS on age at diagnosis, survival improved from 68.5% (95% CI 61.2–74.7) in 1997–2008 to 83.6% (95% CI 76.9–88.6) in 2009–2019 (p = 0.0006). The 5-year OS also increased from 75.7% (95% CI 70.4–81.0) in 1997–2008 to 81.5% (95% CI 76.9–88.6) in 2009–2019 (p = 0.0006). When stratifying the 5-year OS on age at diagnosis, survival improved from 68.5% (95% CI 61.2–74.7) in 1997–2008 to 83.6% (95% CI 76.9–88.6) in 2009–2019 (p = 0.0006). The 5-year OS also increased from 75.7% (95% CI 70.4–81.0) in 1997–2008 to 81.5% (95% CI 76.9–88.6) in 2009–2019 (p = 0.0006). When stratifying the 5-year OS on age at diagnosis, survival improved from 68.5% (95% CI 61.2–74.7) in 1997–2008 to 83.6% (95% CI 76.9–88.6) in 2009–2019 (p = 0.0006). The 5-year OS also increased from 75.7% (95% CI 70.4–81.0) in 1997–2008 to 81.5% (95% CI 76.9–88.6) in 2009–2019 (p = 0.0006). When stratifying the 5-year OS on age at diagnosis, survival improved from 68.5% (95% CI 61.2–74.7) in 1997–2008 to 83.6% (95% CI 76.9–88.6) in 2009–2019 (p = 0.0006). The 5-year OS also increased from 75.7% (95% CI 70.4–81.0) in 1997–2008 to 81.5% (95% CI 76.9–88.6) in 2009–2019 (p = 0.0006).
### Table 3: Five-year overall survival among children with CNS tumors diagnosed between 1997 and 2019 according to ICCC-3 subgroups, by gender, age at diagnosis, localization, and time period

|                  | III-CNS 5-y OS (95% CI) | IIIa-Ependymomas and choroid plexus tumors 5-y OS (95% CI) | IIB-Astrocytomas 5-y OS (95% CI) | IIIc-Embryonal tumors 5-y OS (95% CI) | IIId-Other gliomas 5-y OS (95% CI) | IIIe-Other specified tumors 5-y OS (95% CI) | IIIF-Unspecified 5-y OS (95% CI) | Xa-Germ cell tumors 5-y OS (95% CI) | Unclassified 5-y OS (95% CI) |
|------------------|-------------------------|-----------------------------------------------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------------------|----------------------------------|---------------------------------|-------------------------------|
| **Gender**       |                         |                                                           |                               |                                     |                                   |                                             |                                  |                                 |                               |
| Boys             | 78.0 (73.8–81.6)        | 72.0 (54.0–84.0)                                          | 83.1 (76.4–88.0)              | 59.2 (47.8–69.0)                    | 72.3 (52.1–85.1)                  | 93.0 (84.2–96.6)                           | 80.0 (40.9–94.6)                 | 100                             | 65.5 (46.3–79.2)               |
| Girls            | 76.7 (72.5–80.4)        | 67.0 (48.3–80.2)                                          | 84.6 (78.9–88.9)              | 59.4 (46.6–70.2)                    | 50.4 (31.6–66.5)                  | 88.7 (77.7–94.4)                           | 100                              | 87.1 (57.3–96.6)               | 62.2 (41.1–77.6)               |
| **Age at diagnosis** |                       |                                                           |                               |                                     |                                   |                                             |                                  |                                 |                               |
| 0–4 years        | 76.1 (71.2–80.3)        | 66.6 (49.9–78.8)                                          | 90.0 (83.9–93.8)              | 54.7 (41.7–66.0)                    | 77.3 (50.1–90.8)                  | 84.8 (67.2–93.4)                           | 75.0 (12.8–96.1)                 | 88.9 (43.3–98.4)               | 50.4 (30.3–67.5)               |
| 5–14 years       | 78.1 (74.4–81.4)        | 74.5 (0.54–0.87)                                          | 80.0 (74.1–84.6)              | 62.6 (51.4–72.0)                    | 54.6 (38.3–68.2)                  | 92.7 (86.0–96.3)                           | 90.9 (50.8–98.7)                 | 94.7 (68.1–99.9)               | 75.3 (56.6–86.8)               |
| **Localization** |                         |                                                           |                               |                                     |                                   |                                             |                                  |                                 |                               |
| Supratentorial   | 86.5 (82.7–89.3)        | 81.0 (60.2–91.6)                                          | 84.9 (78.7–89.4)              | 58.8 (32.5–77.8)                    | 86.1 (67.0–94.6)                  | 93.9 (87.7–97.1)                           | 81.8 (44.7–95.1)                 | 94.1 (65.0–99.2)               | 84.1 (62.9–93.7)               |
| Infratentorial   | 70.0 (65.2–74.4)        | 57.6 (37.0–73.6)                                          | 86.9 (80.6–91.3)              | 58.4 (49.3–66.5)                    | 38.6 (21.3–55.6)                  | 79.6 (39.3–94.5)                           | 100                              | 100                             | 55.2 (32.8–72.9)               |
| **Period**       |                         |                                                           |                               |                                     |                                   |                                             |                                  |                                 |                               |
| 1998–2008        | 73.0 (68.9–76.7)        | 63.0 (47.5–75.2)                                          | 79.4 (73.0–84.4)              | 60.0 (49.1–69.3)                    | 62.5 (40.3–78.4)                  | 85.7 (76.2–91.6)                           | 87.5 (38.7–91.1)                 | 86.7 (56.4–96.5)               | 50.0 (31.9–65.7)               |
| 2009–2019        | 83.2 (79.2–86.4)        | 82.3 (60.1–93.2)                                          | 88.7 (83.1–92.6)              | 58.4 (44.6–69.9)                    | 60.3 (42.2–74.4)                  | 98.2 (87.8–99.9)                           | 85.7 (33.4–97.9)                 | 100                             | 81.3 (60.6–91.8)               |

Abbreviations: 5-y OS, Five-year overall survival; Infratentorial: cerebellum, brain stem; Supratentorial: cerebrum, supratentorial central area, hypothalamic or pituitary region, optic nerve, pineal gland.
The risk of death according to univariate and multivariate analyses of gender, age group, tumor localization, and time period is presented in Table 4. A statistically significant reduction of the risk of death was observed in children diagnosed with tumors in 2009–2019 compared to 1997–2008 and in supratentorial tumors compared to infratentorial tumors.

### DISCUSSION

This comprehensive and up-to-date study of incidence, survival, and treatment data accurately reflects the incidence, survival, and primary treatment of CNS tumors diagnosed in children aged less than 15 years in Denmark in the period 1997–2019. Based on almost complete national register data, 949 tumors were identified in the 23-year study period. We included both benign and malignant tumors according to FIGURE 2  Survival of CNS tumors in Denmark in children 0–14 years old. (A) Overall survival from 1997–2019 (B) Survival in children diagnosed from 1997–2008 compared with 2009–2019 ($p < 0.0001$) (C) Survival in children aged 0–4 years diagnosed in 1997–2008 or 2009–2019 ($p = 0.0006$) (D) Survival in children aged 5–14 years diagnosed in 1997–2008 or 2008–2019 ($p = 0.16$)

| Table 4  | Hazard ratios of risk of death according to gender, age, localization, and time period evaluated by univariate and multivariate analyses using Cox proportional hazards model |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|          | **Univariate**                                                                                                                                   | **Multivariate**                                                                 |
| Gender   |                                                                                                                                                 |                                                                                     |
| Boys     | Ref                                                                                                                                             | Ref                                                                                  |
| Girls    | 1.09 (0.84–1.41)                                                                                                                              | 1.13 (0.88–1.47)                                                                    |
| Age      |                                                                                                                                                 |                                                                                     |
| 0–4 years| Ref                                                                                                                                             | Ref                                                                                  |
| 5–14 years| 0.88 (0.68–1.15)                                                                                                                             | 0.89 (0.68–1.16)                                                                    |
| Localization |                                                                                                                                           |                                                                                     |
| Supratentorial | Ref                                                                                                                                         | Ref                                                                                  |
| Infratentorial | 2.14 (1.60–2.88)                                                                                                                               | 2.16 (1.61–2.90)                                                                    |
| Period   |                                                                                                                                                   |                                                                                     |
| 1998–2008| Ref                                                                                                                                             | Ref                                                                                  |
| 2009–2019| 0.62 (0.47–0.82)                                                                                                                               | 0.63 (0.47–0.83)                                                                    |
the International Classification of Childhood Cancer main group III and subgroup Xa as well as treatment information.

### 4.1 Incidence

We found an annual ASR of 42.1 per million person-years, which is broadly similar to results reported for the same time period from other high-income countries such as France, the United Kingdom, Australia, Canada, and the United States.\(^{2,11–13,21}\) The incidence was stable between 1997 and 2019 with only minor fluctuations. High survival and incidence rates are positively associated with the national per capita income level\(^{22,23}\) and are probably related to better diagnostic facilities and access to treatment.

An increased incidence of CNS tumors has been reported in both Denmark and worldwide throughout the mid-1980s as new diagnostic technologies were implemented and the use of MRI became widespread;\(^{8,24}\) however, a relatively stable incidence has been reported in Denmark in children aged 0–19 years from 1977 to 2014.\(^{10}\) We included children 0–14 years, and our finding that incidence rates were stable after 2000 is in line with other studies from Denmark and Europe.\(^{4,10,12,13}\) Other register-based studies have reported an increased overall incidence in Europe and especially in Western Europe.\(^{3}\) Not all studies are complete in their registration and may differ in registration practices, which previously has been addressed,\(^{25}\) thus contributing to the complexity of international comparison.

The most common histological type, astrocytoma, accounted for 40% of all CNS tumors in our study, whereas the most frequent single histological type was pilocytic astrocytoma, accounting for 52% of astrocytomas and 21% of all histological types, which is similar to results from previous studies.\(^{11}\) As pilocytic astrocytoma accounts for 21% of all histological types in this study, future analyses may show an artificial increase in the proportion of benign compared to malignant tumors.

We provided incidence rates not only of the most frequent long-established histological types, but also of newer entities in the third edition of the ICD-O such as dysembryoblastic neuroepithelial tumor (DNET) and ATRT.\(^{17}\) DNET is a low-grade glio-neuronal tumor with an incidence similar to gangliogioma, accounting for 43% of mixed glial-neuronal tumors in our study, which is comparable to other studies.\(^{11}\) ATRT (9408/3) is an aggressive histological type and the second most common embryonal tumor after medulloblastoma. As ATRT often presents in the first 2 years of life, radiation treatment is commonly withheld to protect the immature brain. Due to improved diagnostics, ATRT became an independent entity in the same ICCC-3 subgroup after the year 2000. Previously, ATRT could be interpreted as medulloblastoma when located in the cerebellum in children aged 0–2 years.\(^{6,26}\)

As new entities arise, others are reclassified, as illustrated by the continuous updates of the WHO classification.\(^{27}\) Primitive neuroectodermal tumors of the CNS (CNS-PNET) are highly malignant neoplasms, but neuropathologic diagnosis has been challenging due to a lack of defining molecular markers and a histologic overlap with other high-grade neuroepithelial tumors.

In contrast to other population-based studies on incidence rates, we also provided information on treatment. Many tumors are of benign origin, and more than one-third of the included tumors (39%) were treated with surgery alone without chemotherapy and radiation, whereas malignant tumors require multimodal treatment.\(^{28}\) Childhood CNS tumors constitute a highly heterogeneous group, where different treatment modalities are used. Radiation therapy is preferably postponed or avoided in children younger than 4 years due to potential side effects such as cognitive impairment. Chemotherapy is preferred in young children with malignant, unresectable, or recurrent tumors.

Children were offered proton therapy abroad, if found beneficial. In Denmark, proton therapy became available for children in 2019.

### 4.2 Survival

Overall 5-year survival rates for Danish children with CNS tumors were similar to those reported in France, Sweden,\(^{6}\) and the United States,\(^{29}\) but survival rates can be difficult to compare because selection criteria differ. Data from the United States were based on SEER Statistics for children 0–19 years of age, and a 5-year survival rate including benign tumors from 2010 to 2016 of 74.9% was reported. In our study, 5-year overall survival rate improved from 73.0% in 1997–2008 to 83.2% in 2009–2019. The improved overall survival was statistically significant in children aged 0–4 years, where the 5-year overall survival increased from 68.5% in 1997–2008 to 83.6% in 2009–2019. In the years prior to our study period, a Danish study reported a remarkable improvement of the 10-year survival in Danish children aged 5–14 years. The survival increased from 59% in 1980–1987 to 74% in 1988–1996,\(^{5}\) which probably explains why we did not find a significant increase in 5-year overall survival for children aged 5–14 years in our study.

Over the last two decades, cancer survival has increased remarkably due to advances in molecular characterization of the tumors\(^{30}\) as well as improved surgery, chemotherapy, and radiation protocols in Denmark and in...
other countries. Although the 10-year survival exceeded 70% in our study, this number included 39% of benign tumors treated with surgery alone. It is well known that survival differs considerably between histological types. Malignant CNS tumors such as embryonal tumors or glioblastoma still have a poor prognosis, and the OS of these tumors continued to decline 5–10 years after diagnosis. Future perspectives on how to increase survival of children with malignant tumors must include studies of genetic profiling and how genetic profiling could lead to better treatment regimens.

Finally, our analyses showed that supratentorial tumors or tumors diagnosed in the more recent time period had more favorable prognostic factors. Younger children have been reported to have poorer survival in other studies, but we were not able to show any difference in survival by either age group or gender. This might be due to the fact that malignant tumors are often located in fossa posterior combined with better resection possibilities in the supratentorial area. However, our results should be interpreted with caution, as our study lacks important clinical data such as tumor grade, which probably has an impact on survival.

4.3 Strengths and limitations

Major strengths of this study were the long study period and the high-quality data based on the DCCR with practically complete coverage. The diagnosis and location of the tumor as well as cancer treatment were validated in medical records. We also excluded all non-CNS tumors originally registered as CNS tumors, yielding precise incidence rates of true CNS tumors.

The classification system of CNS tumors was changed by WHO in 2016 and continuously updated. It is now based on molecular biology in combination with histological parameters to define several tumor entities; thus WHO formulated a new concept of how diagnoses should be structured in the molecular era. We were not able to reclassify tumors diagnosed before 2016 to WHO 2016 classification scheme. To use the new classification system retrospectively we would require new immune and next-generation sequencing evaluations to prevent misclassification. Genetic profiling of selected tumor biopsies has already proven that diagnoses can be changed. In the future, with genetic profiling of every single tumor biopsy, the histological distribution may thus be altered. Furthermore, it is important to improve the quality of data collected in registries by adding molecular information and by having uniform complete registration according to recommendations for coding central nervous system tumors.

In conclusion, the present study confirms the results from other recent publications that have reported an incidence of childhood CNS tumors of close to 40 per million person-years. Incidence rates are stable but remain among the highest in the world. Survival has improved especially among younger children with CNS tumors. Still, some histological types have a particularly poor prognosis.

ACKNOWLEDGMENTS

The authors thank The Danish Clinical Quality Program–National Clinical Registries (RKKP) for data provided from the Danish Childhood Cancer Registry.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ETHICAL APPROVAL AND CONSENT TO PARTICIPATE

The study was ethically approved by the Central Denmark Region Committee on Health Ethics (file number: 1–10–72–65–19) and relevant data protection agency (Central Denmark Region, file number: 1–16–02–109–19). The study was performed in accordance with the Declaration of Helsinki.

DATA AVAILABILITY STATEMENT

The study was ethically approved by the Central Denmark Region Committee on Health Ethics (file number: 1–10–72–65–19) and relevant data protection agency (Central Denmark Region, file number: 1–16–02–109–19). The study was performed in accordance with the Declaration of Helsinki.

ORCID

Anne Sophie Lind Helligsoe https://orcid.org/0000-0003-4956-4897
Line Kenborg https://orcid.org/0000-0002-3584-6570
Louise Tram Henriksen https://orcid.org/0000-0002-9350-1538
Henrik Hasle https://orcid.org/0000-0003-3976-9231
Jeanette Falck Winther https://orcid.org/0000-0002-3440-5108

REFERENCES

1. Kyu HH, Stein CE, Boschi Pinto C, et al. Causes of death among children aged 5–14 years in the WHO European Region: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Child Adolesc Health. 2018;2(5):321-337.
2. Baade PD, Youlden DR, Valery PC, et al. Trends in incidence of childhood cancer in Australia, 1983–2006. Br J Cancer. 2010;102(3):620-626.
3. Steliarova-Foucher E, Fidler MM, Colombet M, et al. Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991–2010 (Automated Childhood Cancer Information System): a population-based study. *Lancet Oncol.* 2018;19(9):1159-1169.

4. Schmidt LS, Schmiegelow K, Lahteenmaki P, et al. Incidence of childhood central nervous system tumors in the Nordic countries. *Pediatr Blood Cancer*. 2011;56(1):65-69.

5. Raaschou-Nielsen O, Sorensen M, Carstensen H, et al. Increasing incidence of childhood tumours of the central nervous system in Denmark, 1980–1996. *Br J Cancer*. 2006;95(3):416-422.

6. Lannerber B, Sandstrom PE, Holm S, et al. Classification, incidence and survival analyses of children with CNS tumours diagnosed in Sweden 1984-2005. *Acta Paediatr.* 2009;98(10):1620-1627.

7. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third edition. *Cancer*. 2005;103(7):1457-1467.

8. Smith MA, Freidlin B, Ries LA, Simon R. Trends in reported incidence of primary malignant brain tumors in children in the United States. *J Natl Cancer Inst*. 1998;90(17):1269-1277.

9. Black WC. Increasing incidence of childhood primary malignant brain tumors–enigma or no-brainer? *J Natl Cancer Inst*. 1998;90(17):1249-1251.

10. Grabas MR, Kjaer SK, Frederiksen MH, et al. Incidence and time trends of Childhood cancer in Denmark, 1943–2014. *Acta Oncologica (Stockholm, Sweden).* 2020;59(5):588-595.

11. Stiller CA, Bayne AM, Chakraborty A, Kenny T, Chumas P. Incidence of childhood CNS tumours in Britain and variation in rates by definition of malignant behaviour: population-based study. *BMC Cancer*. 2019;19(1):139.

12. Desandes E, Guissou S, Chastagner P, Lacour B. Incidence and survival of children with central nervous system primitive tumors in the French National Registry of Childhood Solid Tumors. *Neuro-Oncol*. 2014;16(7):975-983.

13. Larouche V, Toupin AK, Lalonde B, Simonyan D, Jabado N, Perreault S. Incidence trends in pediatric central nervous system tumors in Canada: a 15 years report from Cancer and Young People in Canada (CYP-C) registry. *Neuro-Oncol Adv*. 2020;2(1):vdaa012.

14. Bertuccio P, Alicandro G, Malvezzi M, et al. Childhood cancer mortality trends in Europe, 1990–2017, with focus on geographic differences. *Cancer Epidemiol.* 2020;67:101768.

15. Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study. *Lancet Oncol*. 2014;15(1):35-47.

16. Schroder H, Rechnitzer C, Wehner PS, et al. Danish childhood cancer registry. *Clin Epidemiol*. 2016;8:461-464.

17. World Health Organization. International classification of diseases for oncology (ICD-O) – 3rd edition, 1st revision. 3rd ed. Geneva, 2013.

18. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. *Acta Neuropathol.* 2016;131(6):803-820.

19. Statistics Denmark – StatBank.dk/5a

20. Bray FFJ. Chapter 7: age standardization. In: Forman D, Bray F, Brewster DH, eds. *Cancer Incidence in Five Continents*. Scientific Publications: International Agency for Research on Cancer; 2014.

21. Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. *Neuro-oncol.* 2015;17(Suppl:4):iv1-iv62.

22. Lubega J, Kimutai RL, Chintagumpala MM. Global health disparities in childhood cancers. *Curr Opin Pediatr*. 2021;33(1):33-39.

23. Howard SC, Metzger ML, Willimas JA, et al. Childhood cancer epidemiology in low-income countries. *Cancer*. 2008;112(3):461-472.

24. Steinberg EP. The status of MRI in 1986: rates of adoption in the United States and worldwide. *Am J Roentgenol*. 1986;147(3):453-455.

25. Gatta G, Peris-Bonet R, Visser O, et al. Geographical variability in survival of European children with central nervous system tumours. *Euro J Cancer*. 2017;82:137-148. 10.1016/j.ejca.2017.05.028.

26. Burger PC, Yu I-T, Tihan T, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. *Am J Surg Pathol.* 1998;22(9):1083-1092.

27. Ellison DW, Aldape KD, Capper D, et al. cIMPACT–NOW update 7: advancing the molecular classification of ependymal tumors. *Brain Pathol.* 2020;30(5):863-866.

28. Fruhwald MC, Rutkowsi S. Tumors of the central nervous system in children and adolescents. *Deutsches Arzteblatt International*. 2011;108(22):390-397.

29. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969-2017) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, released December 2019. Underlying mortality data provided by NCHS. (www.seer.cancer.govwww.cdc.gov/nchs).

30. Kumar R, Liu APY, Orr BA, Northcott PA, Robinson GW. Advances in the classification of pediatric brain tumors through DNA methylation profiling: from research tool to frontline diagnostic. *Cancer*. 2018;124(21):4168-4180.

31. Girardi F, Allemani C, Coleman MP. Worldwide trends in survival from common childhood brain tumors: a systematic review. *J Glob Oncol*. 2019;5:1-25.

32. Magnani C, Aareleid T, Viscomi S, Pastore G, Berrino F. Variation in survival of children with central nervous system (CNS) malignancies diagnosed in Europe between 1978 and 1992: the EUROCASE study. *Euro J Cancer (Oxford, England : 1990).* 2001;37(6):711-721.

33. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro-Oncology*. 2021;23(8):1231-1251.

34. Østrup O, Nysom K, Scheie D, et al. Importance of comprehensive molecular profiling for clinical outcome in children with recurrent cancer. *Front Pediatr*. 2018;6:114.

35. Kline CN, Joseph NM, Grenert JP, et al. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. *Neuro-Oncology*. 2017;19(5):699-709.

36. Pajtler K, Witt H, Still M, et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. *Cancer Cell*. 2015;27(5):728-743.
37. Recommendations for coding Tumours of the Brain and Central Nervous System. https://encr.eu/sites/default/files/pdf/brainncs.pdf.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Helligsoe ASL, Kenborg L, Henriksen LT, Udupi A, Hasle H, Winther JF. Incidence and survival of childhood central nervous system tumors in Denmark, 1997–2019. Cancer Med. 2022;11:245–256. doi:10.1002/cam4.4429